🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against superbug strains of the pathogen, according to scientists.

A Global Health Concern

The sexually transmitted infection are on the rise worldwide, with estimates suggesting over 82 million instances each year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Results and Global Access

As per findings released by a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians on the front lines have expressed optimism. The availability of a one-pill regimen of this kind is described as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for patients and to prevent the spread of extremely resistant gonorrhoea globally.